Apellis Pharmaceuticals, Inc. (APLS) Tops Q2 EPS by 34c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q2 EPS of ($1.02), $0.34 better than the analyst estimate of ($1.36). Revenue for the quarter came in at $95 million versus the consensus estimate of $70.24 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales